Medicare Denies One in Four Glucose Monitor Claims — 67.6% Had No Documentation At All
Test strips are the least glamorous line item in a DME warehouse and one of the most reliably denied. The coverage rule is a quantity: 100 strips a quarter for a beneficiary not on insulin, 300 for one who is. Go above either number and three separate things have to be in the practitioner's record, and the third one — evidence that the patient actually tests that often — is almost never there.
Compliance alert: CMS updated its glucose monitor compliance guidance in February 2026, and the numbers in it are worse than the DMEPOS average. The 2024 Medicare Fee-for-Service Supplemental Improper Payment Data puts the improper payment rate for glucose monitors at 25.2%, roughly $278.5 million. Of that, 67.6% was claims where reviewers found no documentation, and another 26.6% was insufficient documentation. Together those two categories account for 94.2% of the error. Almost none of it is a coverage argument.
A pharmacy referral comes over the fax on a Thursday. Type 2 diabetic, 71 years old, on basal-bolus insulin, checking before every meal and at bedtime plus a couple of overnight checks after a bad week. The endocrinologist's order says 600 test strips and 600 lancets per 90 days. The diagnosis is right there. The patient is unambiguously insulin treated. The order is signed, dated and legible, and it goes out the door the same afternoon.
Fourteen months later a CERT sample pulls the claim. The finding is not that the patient did not need the strips. It is that the record does not establish the beneficiary was testing at a frequency that corroborates 600 strips a quarter. There is no log. There is no narrative statement. The endocrinologist's note says "continue current regimen, checking blood sugars regularly." Medicare pays for 300 and recoups the rest, on every quarter in the lookback.
Two numbers, and the one that matters is insulin
LCD L33822 sets the quantity of test strips (A4253) and lancets (A4259) that Medicare will pay for by usual medical need, and it draws exactly one line. The line is insulin, and the policy says so directly: coverage depends on "whether or not the beneficiary is being treated with insulin administrations, regardless of their diagnostic classification as having Type 1 or Type 2 diabetes mellitus."
- Not currently treated with insulin: up to 100 test strips and up to 100 lancets every 3 months, if the two basic coverage criteria are met.
- Currently treated with insulin: up to 300 test strips and up to 300 lancets every 3 months, on the same two basic criteria.
The two basic criteria are lighter than most people expect. The beneficiary has diabetes, with a diagnosis code from the list in the policy article. And the treating practitioner has concluded that the beneficiary or their caregiver has sufficient training on the particular device prescribed, which the policy says is evidenced by a prescription for the appropriate supplies and frequency of testing. Miss either one and every testing supply on the claim is denied as not reasonable and necessary, not just the excess.
"Type 1 versus Type 2 does not appear anywhere in the utilization rule. The only clinical fact that moves the number is whether the patient takes insulin."
The third criterion nobody has
Above 100 strips for a non-insulin patient, or above 300 for an insulin patient, the LCD switches to high utilization and adds three conditions. All three have to be satisfied. Here is what they actually ask for:
(a) The two basic coverage criteria are still met. This one is usually fine.
(b) Within the six months before ordering quantities that exceed the guidelines, the treating practitioner had an in-person or Medicare-approved telehealth visit with the beneficiary to evaluate their diabetes control and their need for the specific quantity that exceeds the usual amount. Two things are being asked for in one sentence. A diabetes follow-up visit is not enough on its own. The visit has to touch the quantity.
(c) Every six months, for continued dispensing of the higher quantity, the treating practitioner must verify adherence to the high utilization testing regimen. This is a recurring obligation on a physician who has no financial stake in your claim and no calendar reminder tied to your billing cycle.
Then Policy Article A52464 adds the piece that decides most reviews. For beneficiaries who exceed the usual utilization amounts, the medical record must contain enough information to determine that the beneficiary is actually testing at a frequency that corroborates the quantity of supplies that have been dispensed. The article gives two acceptable forms: a specific narrative statement that adequately documents the frequency at which the beneficiary is actually testing, or a copy of the beneficiary's log.
So the artifact a reviewer wants is a log kept by the patient, sitting in the ordering practitioner's chart at another organization, covering a period that lines up with the quarter you billed. If that practice does not routinely scan glucose logs into the record, the log does not exist in any form Medicare will accept, and it cannot be recreated once the review letter arrives.
The quantity on the order is the claim.
DocuFindr reads the order, the diagnosis, the insulin status, and the visit history against the utilization thresholds before supplies ship — so the missing log is a phone call this week instead of a recoupment next year.
Where the file breaks
| Requirement | What the record must contain | Where it usually breaks | Risk |
|---|---|---|---|
| Diabetes diagnosis | A covered ICD-10 code from the list in Policy Article A52464, on the claim and supported in the record | CMS names "lacking a documented diagnosis code for diabetes" as a top reason strip claims deny. It looks impossible to miss and it is missed constantly on refills | High |
| Training and frequency | Practitioner has concluded the beneficiary or caregiver is trained on the specific device, evidenced by a prescription for the appropriate supplies and frequency of testing | Orders arrive with a quantity and no testing frequency. The frequency is what the policy treats as the evidence | High |
| Insulin status | Clear documentation of whether the beneficiary is currently treated with insulin administrations | Charts say "diabetic, on medication." That sets the threshold at 100, not 300, and it sets the modifier too | High |
| High-utilization visit | In-person or Medicare-approved telehealth visit within 6 months prior to ordering the excess quantity, addressing diabetes control and the specific quantity | A visit exists but it is 8 months old, or it never mentions how many strips the patient needs | Highest |
| Corroborating log | A narrative statement of actual testing frequency, or a copy of the beneficiary's testing log, in the practitioner's record | Almost always absent. Nobody scans patient logs, and "checks sugars regularly" corroborates nothing | Highest |
| Six-month re-verification | Practitioner verifies adherence to the high utilization regimen every 6 months for continued dispensing | Set and forget. The first quarter is documented, quarters three through eight are not, and the lookback covers all of them | High |
| Facility overlap | Dates of service that do not fall inside a covered inpatient hospital or Part A SNF stay | CMS lists both overlaps by name as causes of strip denials. A 90-day ship date crosses an admission nobody on the DME side saw | Medium |
| Refill contact | Documented affirmative response from the beneficiary before dispensing, contact no sooner than 30 days before the current supply ends | Auto-ship on a pre-set cycle. The LCD prohibits it even when the beneficiary previously authorized it | High |
The modifier is a clinical statement, and it is on every line
Blood glucose monitors, their related supplies and CGM devices all carry a mandatory modifier on every claim submitted. There is no default and no blank option.
- KX if the beneficiary is insulin treated.
- KS if the beneficiary is non-insulin treated.
- The policy article adds one prohibition in its own sentence: KX must not be used for a beneficiary who is exclusively treated with oral hypoglycemic agents.
KX means something different here than it does in the rest of the DMEPOS world. In most policies KX is an attestation that all coverage criteria are met and evidenced in your files. In this policy it is a clinical fact about the patient's medication. Billing KX on an oral-agent-only patient because the quantity is high is not an aggressive modifier choice. It is a false statement about the treatment regimen, and it sits on a claim that also asks for three times the covered quantity.
Two more modifier rules catch people. Adjunctive CGMs coded E2102 and their supplies coded A4238 are FDA Class III, so every claim for those codes must carry the KF modifier, and a line billed without it is rejected as missing information rather than denied. Rejected claims have no appeal rights. They come back on a report and rejoin a work queue. For non-adjunctive CGMs coded E2103 and supply allowance A4239, KF depends on whether that specific device is Class III, and the policy tells suppliers to confirm classification with the FDA or the manufacturer before billing rather than guessing.
The CGM collision that voids the strip line
This one is expensive because both claims look correct in isolation.
A non-adjunctive CGM can be used to make treatment decisions without a stand-alone meter to confirm the reading. The LCD therefore says non-adjunctive CGM devices replace standard home BGMs and their related supplies, and it lists the replaced codes explicitly: E0607, E2100, E2101, plus A4233 through A4259. Claims for a BGM and related supplies billed in addition to E2103 and its supply allowance A4239 will be denied. The supply allowance already includes a home meter and related supplies if the patient needs them.
An adjunctive CGM behaves the opposite way. It requires the user to verify a reading with a meter before making treatment decisions, so A4238 does not include a BGM or BGM testing supplies, and those may be billed separately alongside it.
So the same clinical picture, a diabetic on a sensor who also has a meter at home, produces a clean payment or a denial depending on which CGM code is on the other claim. If your organization dispenses strips and someone else dispenses the CGM, you may not find out until the remittance arrives.
Small coding rules with outsized denial rates
- For test strips (A4253), 1 unit of service equals 50 strips. For lancets (A4259), 1 unit of service equals 100 lancets. A 90-day insulin-treated supply at the usual limit is 6 units of A4253 and 3 units of A4259, and transposing those is a routine cause of quantity denials.
- A4271, the cartridge with integrated lancing and blood sample testing, is one unit of service for 50 tests and is treated as equivalent to 50 strips plus 50 lancets. It does not stack with separately billed strips and lancets for the same period.
- More than one spring-powered lancing device (A4258) per 6 months is not reasonable and necessary.
- Medical necessity has not been established for the laser skin piercing device (E0620) or its lens shield cartridge (A4257). Both deny as not reasonable and necessary.
- Alcohol and peroxide (A4244, A4245), betadine and hexachlorophene (A4246, A4247) are non-covered, because the policy holds they are not required for the device to function. Urine test reagent strips (A4250) are non-covered because they are not used with a glucose monitor. Disposable monitors including strips (A9275) are non-covered because they do not meet the definition of DME.
- When a monitor is dispensed, codes A4233 through A4236 are included in the allowance for E0607, E2100, E2101 and E2104. Billing batteries separately with the initial issue creates an unbundling denial on an item worth a few dollars.
Refills: three dates and a hard ceiling
Diabetic supplies are recurring by nature, which means the refill rules apply on every shipment and are audited on every shipment.
Note that the refill rules do not apply to A4238 or A4239. The CGM supply allowance is a monthly allowance billable up to three units per 90 days, and no more than a 90 day supply may be dispensed at a time. Suppliers running one refill workflow across both product lines apply the wrong rule to one of them.
What CMS says the denials actually are
The February 2026 compliance guidance is short about the causes, and the list is not clinical. Denials for diabetic testing strips are attributed to suppliers submitting claims with at least one of three errors: no documented diagnosis code for diabetes, overlap with an inpatient hospital stay, or overlap with a skilled nursing facility stay.
Two of those three are calendar problems. The patient was admitted, the 90 day shipment cycle did not care, and the claim landed inside a period where the facility is responsible for supplies. Nobody at the DME made a clinical error. The order was fine, the diagnosis was fine, the quantity was fine, and the date of service was wrong.
The same guidance also carries an example that is worth reading twice. A supplier bills E2102. The reviewer requests records. The most recent practitioner visit is eight months old rather than within six. The result is an insufficient documentation error and the MAC recoups the payment, on a patient whose clinical need never changed and whose only defect was the date on a progress note.
What this asks of one coordinator
Count what a single quarterly strip refill requires somebody to verify: A diagnosis code that was correct two years ago and may still be on file from an order that has since been revised. An insulin status that determines both the covered quantity and the modifier on every line. A prescription that carries a testing frequency and not only a count. A practitioner visit inside a six month window, addressing a quantity rather than just diabetes control. A patient's own testing log, held by a practice that has no reason to send it to you. A six month re-verification with no natural trigger. A check for a CGM dispensed by somebody else entirely. A unit-of-service conversion where one number is 50 and the neighboring number is 100. A refill contact inside a 30 day window with a documented answer, a delivery inside a 10 day window, and a hard ceiling at three months. And an eligibility check that catches a hospital admission the family never mentioned.
That is one refill, on a product with a margin measured in single-digit dollars, handled by a coordinator with a fax queue that does not stop. Multiply it by a diabetic book of business running on 90 day cycles and the arithmetic explains the 25.2% rate better than any story about medical necessity does. When two-thirds of the error is claims carrying no documentation at all, the failure sits upstream of any clinical judgment. That kind of failure is fixable, and the window to fix it closes when the box ships.
DocuFindr checks the diabetic supply file against the rules that decide it
We validate intake and pre-billing documentation against the coverage criteria, quantity thresholds, coding rules, modifier logic and refill timing that determine the outcome. For testing supplies that means whether the diagnosis is on the claim, whether the order carries a testing frequency, whether insulin status matches the modifier, whether the high-utilization visit is inside six months and speaks to the quantity, whether the corroborating log exists, whether a non-adjunctive CGM voids the strip line, and whether the refill dates hold. Send us a quarter of your diabetic volume and we will show you what it reads like.